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Sodium/glucose cotransporter 1 (SGLT1), an essential active glucose trans-
port protein that helps maintain high intracellular glucose levels, was previ-
ously shown to interact with epidermal growth factor receptor (EGFR);
the SGLT1–EGFR interaction maintains intracellular glucose levels to pro-
mote survival of cancer cells. Here, we explore the role of SGLT1 in triple-
negative breast cancer (TNBC), which is the most aggressive type of breast
cancer. We performed TCGA analysis coupled to in vitro experiments in
TNBC cell lines as well as in vivo xenografts established in the mammary
fat pad of female nude mice. Tissue microarrays of TNBC patients with
information of clinical–pathological parameters were also used to investi-
gate the expression and function of SGLT1 in TNBC. We show that high
levels of SGLT1 are associated with greater tumour size in TNBC. Knock-
down of SGLT1 compromises cell growth in vitro and in vivo. We further
demonstrate that SGLT1 depletion results in decreased levels of phospho-
EGFR, and as a result, the activity of downstream signalling pathways
(such as AKT and ERK) is inhibited. Hence, targeting SGLT1 itself or the
EGFR–SGLT1 interaction may provide novel therapeutics against TNBC.
1. Introduction
Breast cancer is the most frequent cancer type in women
with 1.38 million new cases (23%) each year throughout
the world. It is the fifth leading cause of cancer death
(458 000 deaths worldwide) and, globally, the most fre-
quent female cancer deaths in developing and developed
countries (Ferlay et al., 2010). Triple-negative breast
cancer (TNBC), which lacks expressions of oestrogen,
progesterone and human epidermal growth factor 2
(HER2) receptors, accounts for 10-20% breast cancers
with unsatisfactory therapeutic efficacy (O’Reilly et al.,
2015; Reis-Filho and Tutt, 2008). TNBC is the most
aggressive, high-grade breast cancer type with high risk
of metastasis and poor survival rate compared with the
other breast cancer subtypes. Chemotherapy has been
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the only accepted systemic treatment option for TNBC
for several years to increase the overall survival rate
(Khosravi-Shahi et al., 2018). However, drug resistance
occurs due to its heterogeneity (Du et al., 2015), and this
contributes to the recurrence of the metastatic disease
(Lee and Djamgoz, 2018). Therefore, it is crucial to
identify targeted therapies for TNBC.
Novel targeted therapies, such as endocrine thera-
pies and targeting HER2, were discovered by mapping
the genomic landscapes of breast cancer tumours.
Genomic analysis has led to insights into the classifica-
tion of TNBC such as the separation of TNBC into
different subtypes based on gene expression (Crisci-
tiello et al., 2012; Garrido-Castro et al., 2019; Net-
work, 2012). However, due to its complexity and
heterogeneity, it has been challenging to identify
targeted therapies for TNBC (Lehmann et al., 2011).
Atezolizumab (TECENTRIQ, Roche, Basel, Switzer-
land), an antiprogrammed death-ligand 1 (PD-L1)
monoclonal antibody, was approved recently as a first
targeted therapy for TNBC with combination of
chemotherapy (Abraxane; nab-Paclitaxel, Summit,
NJ, USA) (Cyprian et al., 2019). As atezolizumab plus
chemotherapy combination is only successful for PD-
L1 positive TNBC and TNBC is a heterogeneous dis-
ease, further molecular studies are required to identify
novel therapeutic targets for TNBC. Over the past dec-
ades, potential targeted therapies were discovered for
TNBC by targeting different signalling pathways such
as epidermal growth factor receptor (EGFR) (Crozier
et al., 2016; Nabholtz et al., 2016; Schuler et al., 2012;
Shao et al., 2017; Tredan et al., 2015). However, tar-
geting EGFR pathway was not very successful in part
due to the resistance mechanisms or activation of dif-
ferent signalling pathway(s) (Baselga et al., 2005; Base-
lga et al., 2013; Carey et al., 2012; Spector et al.,
2005). A previous study showed that inhibition of
sodium/glucose cotransporter 1 (SGLT1) sensitized
prostate cancer cells to EGFR inhibitors (gefitinib and
erlotinib) (Wright et al., 2011), although the precise
mechanisms have not been elucidated. Knowing that
SGLT1 mainly interacts with the autophosphorylation
domain of EGFR (Ren et al., 2013), we hypothesized
that SGLT1 may regulate EGFR activity in TNBC.
Sodium/glucose cotransporter 1, encoded by the
SLC5A1 gene in humans, is an active glucose trans-
porter, which utilizes sodium gradients to transport
glucose into cells independent of extracellular glucose
concentration (Rieg and Vallon, 2018; Wright et al.,
2011). Various studies have discovered that SGLT1 is
overexpressed in different cancer types: prostate cancer
(Blessing et al., 2012), ovarian carcinoma (Lai et al.,
2012), oral squamous cell carcinoma (Hanabata et al.,
2012), head and neck carcinoma (Wright et al., 2011),
pancreatic cancer (Casneuf et al., 2008) and colorectal
cancer (Guo et al., 2011). In ovarian carcinoma,
tumour development and poor prognosis of the disease
is associated with the overexpression of SGLT1 (Lai
et al., 2012). Overexpression of SGLT1 also has linked
with higher clinical stages of colorectal cancer (Guo
et al., 2011). Despite of all these observations, the role
of SGLT1 in TNBC was not known. In this study, we
report that SGLT1 is essential for the survival of
TNBC cells in vitro and in vivo. This is achieved, at
least in part, via potentiating EGFR activity.
2. Materials and methods
2.1. Cell culture and transfection
BT549, MDA-MB-468 and MDA-MB-436 cell lines,
which all belong to triple-negative breast carcinoma
cells, were purchased from Cell Bank of the Institute of
Basic medicine, Chinese Academy of Medical Sciences
(Beijing, China), or obtained as NCI-ICBP45 kit pro-
cured through American Type Culture Collection
(ATCC; ATCC Breast Cancer Cell Panel, Manassas,
VA, USA). BT549 cells were cultured in RPMI 1640
medium (Boster, Wuhan, China) supplemented with
10% FBS (Gibco, Carlsbad, USA), 1% antibiotics and
0.023 IUmL1 bovine insulin (Sigma-Aldrich, Saint
Louis, MO, USA). MDA-MB-436 and MDA-MB-468
cells were cultured in Dulbecco’s modified Eagle’s med-
ium (Boster) with 20% or 10% FBS (Gibco) and 1%
antibiotics. All cells were kept at 37 °C and 5% CO2.
The short hairpin RNA (shRNA) product of SGLT1
(sh-SGLT1) with a targeted sequence of ATCTTTC
TCTTATTGGCAA and its negative control (sh-NC)
were purchased from GeneChem (Shanghai, China) and
transfected into cells according to manufacturer’s
instructions. Short interfering RNA (siRNA) oligos
against SGLT1 (MU-007589-01-0002) were purchased
from Dharmacon (Lafayette, CO, USA). Sequences are
available from Dharmacon or upon request. As a nega-
tive control, we used siGENOME RISC-Free siRNA
(Dharmacon). Cells were transfected with the indicated
siRNA oligos at a final concentration of 35 nM using
Dharmafect 2 reagent (Dharmacon).
2.2. Cell viability assay
Short hairpin RNA-transfected cells were seeded into
96-well plates with a density of 1 9 103 cells per well
and allowed to grow for 24, 48 and 72 h. When indi-
cated time arrived, 3-(4,5-Dimethyl-thiazol-2-yl)-2,5-
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diphenyltetrazolium bromide (MTT) solution (Sangon
Biotech, Shanghai, China) was added into the medium
with a final concentration of 0.5 mgmL1. The solu-
tion in each well was carefully sucked after incubation
for 4 h at 37 °C, replaced by 100 µL formazan solubi-
lization solution and gently mix for 10 min. OD values
at 570 nm were measured using Microplate Reader
(Bioteck Instrument, Winooski, VT, USA).
2.3. Western blot analysis
Western blot analysis was performed with lysates from
cells or tissues with urea buffer (8 M urea, 1 M thiourea,
0.5% CHAPS, 50 mM DTT and 24 mM spermine). For
immunoprecipitations, the cells were lysed for 30 min at
4 °C in pNAS buffer [50 mM Tris/HCl (pH 7.5),
120 mM NaCl, 1 mM EDTA and 0.1% Nonidet P-40],
with protease inhibitors. Indicated antibodies and
immunoglobulin G (IgG) agarose were added to the
lysate for 16 h at 4 °C. Immunoprecipitates were
washed four times with cold PBS followed by the addi-
tion of SDS sample buffer. The bound proteins were
separated on SDS polyacrylamide gels and subjected to
immunoblotting with the indicated antibodies. Primary
antibodies were from Abcam (Cambridge, UK)
(SGLT1, 1 : 1000, ab14686; b-actin, 1 : 2000, ab8227;
b-tubulin, 1 : 5000, ab6046; GAPDH, 1 : 2000, ab9385;
Phospho-EGFRTyr1068, 1 : 1000, ab40815), Cell Signal-
ing Technology (Leiden, Netherlands) [SGLT1,
1 : 1000, 5042; Phospho-EGFRTyr1068, 1 : 1000, 3777,
D7A5; EGFR, 1 : 1000, 4267, D38B1; Phospho-AKT
Ser473, 1 : 1000, 9271; Phospho-AKT Thr308,
1 : 1000, 4056, 244F9; AKT, 1 : 1000, 9272; Phospho-
ERK (Thr202/Tyr204), 1 : 1000, 9101; ERK, 1 : 1000,
9102; Cleaved PARP Asp214, 1 : 1000, 9541] and Milli-
pore (Burlington, MA, USA) (PTEN, 1 : 1000, 04-409).
Signals were detected using an ECL detection system
(GE Healthcare) (Chicago, IL, USA) or an Odyssey
imaging system (LI-COR), and evaluated by ImageJ
1.42q software (National Institutes of Health) (Ber-
hesda, MD, USA).
2.4. Immunofluorescence microscopy
Cells were fixed in 4% PBS-paraformaldehyde for
15 min, incubated in 0.1% Triton X-100 for 5 min on
ice, then incubated in 0.2% Fish Skin Gelatine in PBS
for 1 h, and stained for 1 h with an anti-Phospho-
EGFRTyr1068 (1 : 100; Cell Signaling Technology,
3777). Protein expression was detected using Alexa
Fluor (1 : 400; Molecular Probes, Eugene, OR, USA)
for 20 min. TO-PRO-3 (Invitrogen, Waltham, MA,
USA) was used to stain nucleic acids (1 : 2000).
2.5. Animal study
Animal experiments were carried out in accordance with
the guidelines and approved protocols of the Ethics
Committee of Tongji Hospital (Wuhan, China). Specific
pathogen-free (SPF) nude mice (female, 6 weeks) were
purchased from Vital River Laboratory Animal Tech-
nology Co., Ltd. (Beijing, China) and housed under
SPF condition. After adaptation for 1 week in condition
of stable temperature and humidity with 12 h light–dark
cycle, mice were randomly divided into sh-NC group
and sh-SGLT1 group (n = 6 mice per group). ShRNA-
transfected MDA-MB-436 cells were harvested, rinsed
and resuspended in PBS at a concentration of
2 9 108 cellsmL1, which were then placed on ice for
subsequent operation. Orthotopic injection was per-
formed in sterile condition in clean bench according to
protocol described previously (Kocat€urk and Versteeg,
2015) with adaptations. Briefly, after anesthetizing the
mice intraperitoneally with sterilized 2% Avertin
(Sigma-Aldrich) with a dosage of 0.12 mL/10 g weight,
mammary gland was exposed by making a small inci-
sion between the fourth nipple and the midline. A total
of 1 9 107 cells in 50 µL suspension were completely
injected into mammary fat pad located in groin without
leaking. Then, the incisions were sutured and mice were
attended until they gain consciousness. The lengths and
widths of xenografts were measured weekly by vernier
calliper, and volume was calculated using following for-
mula: V (mm3) = 1/2*length*widths2. At the end of
experiment, mice were sacrificed, while xenografts were
completely separated, measured and fixed by 4%
paraformaldehyde for histological staining.
2.6. Immunohistochemical and H/E staining and
scoring
Tissue microarray of TNBC patients with information of
clinical–pathological parameters was purchased from
Outdo Biotech (HBreD090Bc01; Shanghai, China).
Paraffin-embedded sections of xenograft tissues were sub-
jected to deparaffinization and rehydration. H/E staining
of sections was carried out using H/E staining kit (Bey-
otime, Shanghai, China) according to manufacturer’s
instructions. For immunohistochemical staining of tissue
microarray and sections of xenograft and antigen retrie-
val, blocking of non-specific binding and incubation of
primary antibodies at 4 °C overnight was sequentially
conducted. The primary antibodies used were list as fol-
lows: anti-phospho-EGFR (ab40815; Abcam, 1 : 200)
and anti-SGLT1 (ab14686; Abcam, 1 : 100). After incu-
bation with secondary goat anti-rabbit immunoglobulin
conjugated to peroxidase-labelled dextran polymer
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(SV0002; Boster) at 37 °C for 1 h, visualization, counter-
staining with haematoxylin and mounting were per-
formed. Semiquantitative evaluations of protein
expression were scored on the basis of the intensity and
the percentage of phospho-EGFR- or SGLT1-positive
tumour cells as previously described (Wang et al., 2014).
2.7. TCGA data mining and pathway analysis
SLC5A1, mRNA expression z-score (RNA Seq V2
RSEM) and molecular subtypes of breast invasive car-
cinoma (TCGA, Provisional) were obtained from
cBioPortal for Cancer Genomics website (http://
www.cbioportal.org). Molecular subtypes of breast
samples were separated based on ER, PR and HER2
status, and mRNA expression of SGLT1 was analysed
in each subtype in GRAPHPAD PRISM 8 (La Jolla, CA,
USA) by ordinary one-way ANOVA.
Two different data sets, TCGA_BRCA_RPPA-2015-
02-24 and TCGA_BRCA_exp_HiSeqV2-2015-02- 24,
for RPPA protein expression and gene expression RNA-
Seq (IlluminaHiSeq, San Diego, CA, USA), respec-
tively, were extracted from UCSC Cancer Browser
(https://genome-cancer.ucsc.edu/) for the analysis of
genomic matrix data in TNBC samples. The data of
TNBC samples that had SGLT1 mRNA expression
from the cBioPortal for Cancer Genomics website were
aligned with the samples in genomic matrix of TCGA
data for both protein and gene expressions. For both
protein and gene expression data sets, top 20% and bot-
tom 20% of samples were chosen for high and low
SGLT1 expression, respectively. Then, unpaired t-test
was performed to find the significantly different pro-
teins/genes between high and low SGLT1 groups in R
version 3.4.4 (Auckland, New Zealand), P < 0.05. For
the protein expression of AKT_pT308 in TCGA protein
data set, PRISM8 was used to plot scatter dot plot
between high and low SGLT1 groups.
To explore the pathway analysis of the TCGA gene
data analysis, the database for annotation, visualization
and integration discovery (DAVID) functional annota-
tion web tool was conducted (version 6.8; https://david.
ncifcrf.gov (Huang et al., 2009)). A total of 1325 genes,
which were positively correlated with SGLT1 in TCGA
gene data, were analysed with DAVID web tool and
obtained the lists of enriched Kyoto Encyclopedia of
Genes and Genomes pathway, REACTOME pathway,
BIOCARTA, BBID and EC number. A P value ≤ 0.05
was considered significant. The pathways were sorted
from lowest P value, and top 34 pathways were chosen
which then were sorted with highest number of shared
genes. Subsequently, we then plotted that histogram
plot with the top 15 pathways in GRAPHPAD PRISM 8.
2.8. Statistical analysis
Comparison of two groups was statistically calculated
by Student’s t-test. Chi-square test or Fisher exact test
were used to evaluate the relationship of SGLT1
expression and clinical parameters of TNBC. Correla-
tion between expressions of SGLT1 and phospho-
EGFR was analysed using Pearson’s correlation. Data
were shown as mean  SD. Statistical analysis was
conducted using SPSS version 19.0 (Endicott, NY,
USA). Unpaired t-test was performed for TCGA data
analysis in R version 3.4.4. To identify the statistical
difference of AKT_pT308 between high and low
SGLT1 group in TCGA protein data, unpaired t-test
was performed in GRAPHPAD PRISM 8 software.
3. Results
3.1. SGLT1 expression is higher in TNBC, and
this associates with a larger tumour size
The expression of SGLT1 was upregulated in various
cancer types (Blessing et al., 2012; Casneuf et al., 2008;
Guo et al., 2011; Hanabata et al., 2012; Lai et al., 2012;
Wright et al., 2011). To investigate whether the expres-
sion of SGLT1 is different between each molecular sub-
type of breast cancer, TCGA breast invasive carcinoma
(Provisional) data were analysed. The mRNA levels of
SGLT1 (SLC5A) were significantly higher in TNBC and
HER2-positive subtypes than luminal A and luminal B
(Fig. S1). No significant difference between TNBC- and
HER2-positive subtypes was observed (Fig. S1).
In order to examine whether SGLT1 expression levels
correlate with clinical–pathological features in TNBC, we
performed immunohistochemistry staining of SGLT1 in
TNBC tissue microarrays. Table 1 shows clinical and
pathological characteristics of the 90 TNBC patient sam-
ples. We found only tumour size was significantly
affected by SGLT1 expression (Table 1). Representative
images of high and low expression of SGLT1 in TNBC
are shown in Fig. 1A. Tumour size was significantly lar-
ger in high SGLT1 TNBC samples compared with the
low SGLT1 TNBC samples (P = 0.006; Fig. 1B).
3.2. SGLT1 depletion impairs cell viability of
TNBC
Given the fact that SGLT1 levels associate with
tumour size, we next checked whether SGLT1 deple-
tion impairs cell viability. MTT assay was performed
in control or SGLT1-depleted MDA-MB-436, MDA-
MB-468 and BT549 cell lines (Fig. S2). The OD values
1877Molecular Oncology 13 (2019) 1874–1886 ª 2019 The Authors. Published by FEBS Press and John Wiley & Sons Ltd.
H. Liu et al. SGLT1 in TNBC
in MDA-MB-436, MDA-MB-468 and BT549 cells
were significantly decreased in SGLT1-depleted ones
compared with the controls in various time points
(Fig. 2A). We subsequently performed an in vivo study
to determine the effect of SGLT1 knockdown on
tumour growth. MDA-MB-436 tumours were estab-
lished in the mammary fat pad of female nude mice.
As shown in Fig. 2B, tumours were found in four of
six mice where control MDA-MB-436 cells were
injected, whereas only two of six mice had tumours
where SGLT1-depleted MDA-MB-436 cells were
injected. The volume and weight of tumours present in
the mice injected with SGLT1-depleted MDA-MB-436
cells were significantly lower than that in the control
group injected with control cells (Fig. 2B). Hence, a
reduction in SGLT1 expression is able to inhibit
TNBC cell growth in vitro and in vivo.
3.3. TCGA analysis reveals a link between SGLT1
status and AKT signalling in TNBC samples
In order to find how SGLT1 regulates tumour growth,
we analysed data from the TCGA project. Protein
(RPPA) TCGA breast invasive carcinoma data and
Gene, RNASeq (IlluminaHiSeq) TCGA breast invasive
carcinoma data sets were obtained from UCSC Cancer
Genomics Browser (https://genome-cancer.ucsc.edu/).
Protein expression data included 410 breast invasive
carcinoma samples and 142 proteins; and gene expres-
sion data contained 1215 samples and 20530 genes. Both
protein (RPPA) and gene expression, RNASeq (Illu-
minaHiSeq), breast invasive carcinoma samples from
Cancer Genome Browser were aligned with TNBC sam-
ples, as shown in Fig. S1. The alignment showed 59 and
160 TNBC samples in protein (RPPA) and gene, RNA-
Seq (IlluminaHiSeq) data, respectively. In both protein
and gene expression data sets, the top 20% and bottom
20% samples were separated into two groups: high and
low SGLT1-expressing samples, respectively, and
unpaired t-test was performed to find the significantly
different proteins/genes between the groups. A heat
map of protein expression for 19 proteins, including
phosphorylated AKT (AKT_pT308), that were signifi-
cantly different between high and low SGLT1-express-
ing samples (P < 0.05) is shown in Fig. 3A. The scatter
dot plot showed the protein expression of phosphory-
lated AKT (AKT_pT308) for each sample in high and
Table 1. The relationship between patients’ clinical–pathological
characteristics and SGLT1 expression in TNBC. The other P values
were obtained by chi-square test.
Characteristics N
SGLT1
P valueLow expression High expression
Age 90
≤ 50 46 28 18 0.290
> 50 44 21 23
Location 90
Left breast 46 23 23 0.406
Right breast 44 26 18
Grade 90
I–II 36 19 17 0.832
III 54 30 24
Size 86
≤ 2 cm 37 26 11 0.016*
> 2 cm 49 21 28
Positive LN 35
≤ 2 21 10 11 0.728a
> 2 14 5 9
aP value of Fisher’s exact test. The other P values were obtained
by chi-square test. *P < 0.05.
Fig. 1. SGLT1 expression levels associate with tumour size in
triple-negative breast carcinoma (TNBC). (A) Representative SGLT1
staining pattern (high or low SGLT1) in 90 TNBC tissue microarray
cores. Scale bar: 100 lm. (B) The relationship between SGLT1
expression and tumour size in TNBC samples was analysed. Chi-
square test was performed (P = 0.006).
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low SGLT1 groups (Fig. 3B). A total of 2279 signifi-
cantly different genes between high and low SGLT1-ex-
pressing samples are shown by the heat map (Fig. 3C).
To demonstrate whether the significantly positive
genes with SGLT1 in TCGA data set are involved in
the same pathway, DAVID, online website (https://da
vid.ncifcrf.gov) was used to perform a pathway analy-
sis. We found PI3K–AKT signalling pathway is the
top pathway that has the highest hit genes, followed
by Ras signalling and other pathways (Fig. 3D). These
analyses suggested that SGLT1 may interact with
AKT signalling pathway.
3.4. SGLT1 binds EGFR and positively regulates
EGFR activity
Search Tool for the Retrieval of Interacting Genes
(https://string-db.org) analysis showed the interaction
between SGLT1 and EGFR (Fig. S3), which was
reported earlier (Ren et al., 2013; Weihua et al., 2008).
In fact, we also observed EGFR–SGLT1 interaction in
MDA-MB-468 human breast cancer cells. Endogenous
EGFR and SGLT1 co-immunoprecipitated together in
MDA-MB-468 cells (Fig. 4A).
Given that SGLT1 interacts primarily with the auto-
phosphorylation domain of EGFR (Ren et al., 2013),
we asked whether SGLT1 status could also affect
EGFR activity on the other hand. Consistently, the
immunofluorescence signal of phospho-EGFRTyr1068
was at the cell membrane in MDA-MB-468 cells
(Fig. 4B). To test the biological importance of the
observed EGFR–SGLT1 interaction, we examined the
level of phospho-EGFRTyr1068 by immunofluorescence
staining in MDA-MB-468 cells treated with control
small interfering RNA (siRNA) or siRNA against
SGLT1. Importantly, SGLT1 depletion by RNA
Fig. 2. SGLT1 depletion impairs cell viability of TNBC in vitro and in vivo. (A) Knockdown of SGLT1 in BT549, MDA-MB-436 and MDA-MB-
468 cells resulted in cell growth inhibition as performed by MTT assay. Data are represented as a mean value  standard deviation of three
independent experiments. Student’s t-test was conducted to identify statistical differences in each time point. *P < 0.05, **P < 0.01 and
***P < 0.001. (B) Graphs showing tumour volume (P = 0.04) or weight (P = 0.03) present in the mice injected with control or SGLT1-
depleted MDA-MB-436 cells. Pictures of the tumours formed were also shown. Scale bar: 1 cm. Student’s t-test was performed between
control and SGLT1 RNAi groups to identify statistical difference of tumour volume and weight.
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Fig. 3. TCGA analysis reveals a link between SGLT1 status and AKT signalling in TNBC samples. Heat maps of the columns indicate each
individual sample in high and low SGLT1 groups across each protein (A) and gene (C) in TCGA breast invasive carcinoma data, which
obtained from Cancer Genome Browser. Rows indicate protein expressions (RPPA) (A) and gene expressions (IlluminaHiSeq) (C). Dark blue
colour indicates low expression of proteins/genes, and dark pink colour illustrates highly expressed proteins/genes. Unpaired t-test was
analysed to find the significantly different proteins/genes in TCGA breast invasive carcinoma data sets. n represents the number of samples
in each group. (B) Box plot shows the protein expression of AKT_pT308 between high and low SGLT1 groups in TNBC, TCGA breast
invasive carcinoma. *P < 0.05. (D) The genes that were positively regulated with SGLT1 were analysed in DAVID website to show which
pathways are regulated. Histogram shows top 15 pathways based on lowest P value. Y-axis shows the pathways, and top x-axis and
bottom x-axis show the number of shared genes in each pathway and log10 (P value), respectively.
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interference (RNAi) largely abolished the membrane
signal of phospho-EGFRTyr1068 (Fig. 4B). For most of
the analyses described here, we used pools of four
siRNA against each gene (‘SMARTpools’ from Dhar-
macon). However, deconvolution of siRNA pools into
their constituent individual oligonucleotides is an
important step in minimizing the potential for off-tar-
get effects to compromise the analysis of gene knock-
down studies (Echeverri et al., 2006). Figure S4
showed that deconvolution of SGLT1 siRNA
SMARTpool, two out of four different oligonu-
cleotides, clearly led to the downregulation of SGLT1
and reduced level of phospho-EGFRTyr1068.
We next asked whether SGLT1 status could affect
the activity of EGFR downstream pathways, which
was investigated by examining the EGFR signalling
cascade in MDA-MB-468 cells transfected with control
siRNA or SGLT1 siRNA. The basal phosphorylation
levels of EGFR (Tyr1068) and AKT (Ser473 and
Thr308) were reduced in SGLT1-depleted MDA-MB-
468 cells compared with control cells or control
siRNA-treated cells. Total protein levels of EGFR and
AKT, however, were not affected (Fig. 4C). Following
SGLT1 gene silencing in MDA-MB-468 cells, a rapid
and profound loss of cell viability was observed, most
likely resulting from a robust induction of apoptosis.
This is evident by the detection of poly ADP ribose
polymerase (PARP) cleavage, a well-described indica-
tor of effector caspase activation and consequent cell
death (Fig. 4C).
The difference was more notable upon epidermal
growth factor (EGF) treatment. A much stronger
Fig. 4. SGLT1 binds EGFR and positively regulates EGFR activity. (A) Total cell lysates from MDA-MB-468 cells were immunoprecipitated
with an anti-EGFR antibody or control IgG. EGFR and SGLT1 levels are indicated. IgGH indicates IgG heavy chain. (B) Immunofluorescence
staining of Phospho-EGFRTyr1068 (green) in MDA-MB-468 cells transfected with SGLT1 siRNA or control siRNA. TO-PRO-3 (blue) was used
to stain nuclei. Scale bar: 10 µm. (C) Protein expression of Phospho-EGFRTyr1068, EGFR, Phospho-AKT Ser473, Phospho-AKT Ser308, AKT,
Cleaved PARP Asp214 and SGLT1 in MDA-MB-468 cells with indicated treatments. b-tubulin was used as a loading control. (D) Protein
expression of Phospho-EGFRTyr1068, EGFR, Phospho-AKT Ser473, Phospho-ERK (Thr202/Tyr204) and SGLT1 in MDA-MB-468 cells with
indicated treatments. b-tubulin was used as a loading control.
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response induced by addition of EGF was observed in
control siRNA-treated cells compared with SGLT1-de-
pleted MDA-MB-468 cells, reflected by the phosphory-
lation levels of EGFR (Tyr1068), ERK (Thr202/
Tyr204) and AKT (Ser473; Fig. 4D). These data sug-
gest that by binding to EGFR, SGLT1 potentiates
EGFR signalling.
To further validate the in vitro findings, the regula-
tion of EGFR phosphorylation by SGLT1 was investi-
gated in vivo using tumour sections derived from
control shRNA or SGLT1 shRNA-transfected MDA-
MB-436 cells (Fig. 2B). Using adjacent tumour sec-
tions derived from MDA-MB-436–control shRNA
cells, we observed positive SGLT1 and EGFR phos-
phorylation. In tumours derived from MDA-MB-436–
SGLT1 shRNA cells, SGLT1-negative tumour regions
showed reduced levels of EGFR phosphorylation
(Fig. 5). In addition, the correlation of SGLT1
expression and EGFR phosphorylation levels was
analysed in TNBC samples (Fig. 6). High SGLT1 cor-
related with high EGFR phosphorylation levels in
TNBC (P < 0.0001). These observations agree with the
finding that SGLT1 potentiates EGFR signalling in
TNBC.
4. Discussion
Chemotherapy has been the only systemic treatment
option for TNBCs for several years to increase the
overall survival rate of the patients (Khosravi-Shahi
et al., 2018), but chemotherapy resistance is the major
challenge for the treatment of the patients with TNBC
(Lee and Djamgoz, 2018). Therefore, several studies
detected the molecular changes before and after the
chemotherapy to identify potential targeted therapy
for TNBC (Balko et al., 2014). Identification of
Fig. 5. Downregulation of SGLT1 reduces EGFR phosphorylation level in vivo. Adjacent tumour sections from representative cases of
tumour xenografts formed by MDA-MB-436 cells treated with control or SGLT1 shRNA were stained with H/E. The expression of SGLT1
and p-EGFR is also indicated. Scale bars: 100 lm.
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targeted therapy for the patients with TNBC could
help to prevent the risk of resistance of the treatment
option and recurrence of the disease. In this study, we
showed that targeting of SGLT1 has the potential to
treat TNBC. We found SGLT1 status associates with
tumour size in TNBC. Similarly, SGLT1 expression
showed significant association with clinical–pathologi-
cal characteristics and prognosis of ovarian cancer;
SGLT1 overexpression significantly correlated with
increased pT status and poor prognosis (Lai et al.,
2012). Guo et al. (2011) also reported that higher
expression of SGLT1 significantly associated with the
clinical stage of colorectal cancer (Guo et al., 2011).
SGLT1 is an active glucose transporter and plays a
critical role in glucose absorption and retention in the
body (Wright et al., 2011). In cancer cells, a high rate
of glucose uptake is required to meet the increased
energy needs and leads to abnormal growth of cancer-
ous cells (Hanahan and Weinberg, 2011). Depletion or
inhibition of SGLT1 may reduce the energy supply to
the cancer cells. In addition, we demonstrated that
downregulation of SGLT1 dampened EGFR-AKT or
EGFR-ERK pathways activity, which phosphorylates
a plethora of targets to activate the cell cycle, prevent
apoptosis and trigger cellular growth (Downward,
2003; Manning and Cantley, 2007). As a result,
SGLT1 depletion induced apoptosis in TNBC cells
and inhibited their growth in vitro and in vivo. Consis-
tently, overexpression of SGLT1 protected renal
epithelial cells (Ikari et al., 2005) and intestinal epithe-
lial cells (Yu et al., 2008) from apoptosis.
Upon activation by its growth factor ligands, EGFR
undergoes a transition from an inactive monomeric
form to an active homodimer (Yarden and Sch-
lessinger, 1987). EGFR dimerization stimulates its
intrinsic intracellular protein–tyrosine kinase activity.
As a result, autophosphorylation of several tyrosine
residues in the C-terminal domain of EGFR occurs
(Downward et al., 1984; Lemmon et al., 2014). This
autophosphorylation elicits downstream activation and
signalling. For example, growth factor receptor-bound
protein 2 binds activated EGFR at phospho-Tyr1068,
which is crucial to the EGF-induced activation of Ras
signalling pathway (Rojas et al., 1996). It was demon-
strated autophosphorylation of EGFR is taking place
primarily by activated EGFR located at the cell mem-
brane (Sousa et al., 2012). Downregulation of SGLT1
by RNAi resulted in the decreased level of phospho-
EGFRTyr1068, and as a result, the activity of down-
stream signalling pathways (such as AKT and ERK)
was inhibited, suggesting that SGLT1 may facilitate
the autophosphorylation of EGFR upon ligand bind-
ing. This result was also supported by significantly
positive correlation between phospho-EGFR and
SGLT1 in TNBC samples.
In line with the previous report indicating that loss
of EGFR protein but not its tyrosine kinase activity
sensitized cancer cells to chemotherapeutic agent (Wei-
hua et al., 2008), EGFR tyrosine kinase inhibitors did
not produce therapeutic effects for certain cancers
(Cohen et al., 2003; Dancey and Freidlin, 2003;
Fukuoka et al., 2003). It has been highlighted EGFR
tyrosine kinase inhibitors or monoclonal antibodies
against TNBC showed low response rate, and the com-
bination treatment with tyrosine kinase inhibitors or
monoclonal antibodies and chemotherapy also showed
low response rate and no benefits in the survival rate
of patients (Baselga et al., 2013; Carey et al., 2012;
Fig. 6. SGLT1 expression levels positively correlate with EGFR
phosphorylation in TNBC. (A) Adjacent tumour sections from
representative cases show SGLT1 and p-EGFR expression in
TNBC. Scale bar: 100 lm. (B) The relationship between SGLT1
expression and EGFR phosphorylation was analysed by Pearson
correlation test (R = 0.41, n = 90, P < 0.0001).
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Finn et al., 2009; Lee and Djamgoz, 2018; Schuler
et al., 2010). Therefore, further works are needed to
find out the best way to use EGFR targeted therapy in
TNBC. EGFR–SGLT1 interaction stabilizes SGLT1
for the high uptake of glucose by cancerous cells and
leads to the progression of cancer (Ren et al., 2013;
Weihua et al., 2008). EGFR depletion (Weihua et al.,
2008) or deletion of the SGLT1 interacting domain in
EGFR promoted the downregulation of SGTL1 via
the proteasome machinery (Ren et al., 2013). Together,
targeting SGLT1 itself or EGFR–SGLT1 interaction
might potentially provide novel therapeutics for TNBC
patients.
5. Conclusion
In summary, this study shows that high levels of
SGLT1 are associated with greater tumour size in
TNBC. SGLT1 depletion compromises cell growth
in vitro and in vivo. We further demonstrate that
downregulation of SGLT1 results in decreased levels
of phospho-EGFR, and as a result, the activity of
downstream signalling pathways (such as AKT and
ERK) is inhibited. Hence, SGLT1 is required for the
survival of TNBC via potentiation of EGFR activity.
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